Association of Dopamine Transporter Reduction With Psychomotor Impairment in Methamphetamine Abusers

Woolverton WL, Cervo L, Johanson CE: Effects of repeated methamphetamine administration on methamphetamine self-administration in rhesus monkeys. Pharmacol Biochem Behav 1984; 21:737–741

O’Dea PJ, Murphy B, Balzer C: Traffic and illegal production of drugs in rural America. NIDA Res Monogr 1997; 168:79–89

National Institute on Drug Abuse: Methamphetamine abuse alert. NIDA Notes 1999; 13:15S–16S

Shaw KP: Human methamphetamine-related fatalities in Taiwan during 1991–1996. J Forensic Sci 1999; 44:27–31

Gibb JW, Johnson M, Elayan I, Lim HK, Matsuda L, Hanson GR: Neurotoxicity of amphetamines and their metabolites. NIDA Res Monogr 1997; 173:128–145

Seiden LS, Sabol KE: Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Monogr 1996; 163:251–276

Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ: Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996; 2:699–703

McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA: Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998; 18:8417–8422

Volkow ND, Ding Y-S, Fowler JS, Wang G-J, Logan J, Gatley SJ, Schlyer DJ, Pappas N: A new PET ligand for the dopamine transporter: studies in the human brain. J Nucl Med 1995; 36:2162–2168

Radloff LS: The CES-D Scale: a self-report depression scale for research in the general population. J Applied Psychol Measurement 1977; 1:385–401

Bendriem B, Dewey SL, Schlyer DJ, Wolf AP, Volkow ND: Quantitation of the human basal ganglia with positron emission tomography: a phantom study of the effect of contrast and axial positioning. IEEE Trans Med Imaging 1991; 10:216–222

Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer D, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ, Christman DR: Graphical analysis of reversible binding from time activity measurements. J Cereb Blood Flow Metab 1990; 10:740–747

Logan J, Volkow ND, Fowler JS, Wang G-J, Dewey SL, MacGregor R, Schlyer D, Gatley SJ, Pappas N, King P, Hitzemman R, Vitkun S: Effects of blood flow on [11C] raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab 1994; 14:995–1010

Villemagne V, Yuan J, Wong DF, Dannals RF, Hatzidimitriou G, Mathews WB, Ravert HT, Musachio J, McCann UD, Ricaurte GA: Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 1998; 18:419–427

Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang SC, Phelps ME: Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 1997; 766:113–120

Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S: Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 1993; 90:11965–11969

Asenbaum S, Brucke T, Pirker W, Podreka I, Angelberger P, Wenger S, Wober C, Muller C, Deecke L: Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson’s disease. J Nucl Med 1997; 38:1–6

Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF: Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson’s disease. Ann Neurol 1993; 34:423–431

Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ: Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? Ann Neurol 1997; 41:58–64

Volkow ND, Ding Y-S, Fowler JS, Wang G-J, Logan J, Gatley SJ, Hitzemann R, Smith G, Fields F, Gur R, Wolf AP: Dopamine transporters decrease with age in healthy subjects. J Nucl Med 1996; 37:554–558

Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, Levey AI: Immunochemical analysis of dopamine transporter protein in Parkinson’s disease. Ann Neurol 1997; 41:530–539

Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O: Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 67:737–741

Samii A, Markopoulou K, Wszolek ZK, Sossi V, Dobko T, Mak E, Calne DB, Stoessl AJ: PET studies of parkinsonism associated with mutation in the alpha-synuclein gene. Neurology 1999; 53:2097–2102

Rolls ET: Neurophysiology and cognitive functions of the striatum. Rev Neurol (Paris) 1994; 150:648–660

Wallace TL, Gudelsky GA, Vorhees CV: Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. J Neurosci 1999; 19:9141–9148

Itoh J, Nabeshima T, Kameyama T: Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. Eur J Pharmacol 1991; 194:71–76

Mohr E, Fabbrini G, Ruggieri S, Fedio P, Chase TN: Cognitive concomitants of dopamine system stimulation in parkinsonian patients. J Neurol Neurosurg Psychiatry 1987; 50:1192–1196

Marie RM, Barre L, Dupuy B, Viader F, Defer G, Baron JC: Relationships between striatal dopamine denervation and frontal executive tests in Parkinson’s disease. Neurosci Lett 1999; 260:77–80

Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, Racagni G, Corsini GU: Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 1998; 71:2439–2446

Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY: Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 1982; 235:93–103